Targeted therapy in combination with chemotherapy in recurrent and/or metastatic head and neck cancerTargeted therapy in combination with chemotherapy in recurrent and/or metastatic head and neck cancer
Faculty of Medicine and Health Sciences
Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO)
2010Goring-on-Thames :Touch medical media, 2010
European oncology. - Goring-on-Thames, 2005, currens
6(2010):1, p. 43-46
University of Antwerp
Two epidermal growth factor receptor (EGFR)-targeting strategies are used in recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN): monoclonal antibodies and small-molecule tyrosine kinase inhibitors. Thus far, the monoclonal antibody cetuximab has been studied in most detail. Based on the results of two randomised phase III trials, cetuximab in combination with platinum-based chemotherapy should be considered the new standard first-line regimen for patients with recurrent and/or metastatic disease for whom a platinum-based regimen regimen is considered the best treatment option. Other EGFR-directed monoclonal antibodies are under investigation. The role of EGFR tyrosine kinase inhibitors (TKIs) in SCCHN is less well established and early data on other targeted agents have also been disappointing thus far. Dual pathway inhibition may overcome resistance to single pathway inhibition.